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Introduction: Common Variable Immunodeficiency (CVID) is characterized by defective
antibody production and hypogammaglobulinemia. Flow cytometry immunophenotyping
of blood lymphocytes has become of great relevance for the diagnosis and classification
of CVID, due to an impaired differentiation of mature post-germinal-center (GC) class-
switched memory B-cells (MBC) and severely decreased plasmablast/plasma cell (Pb)
counts. Here, we investigated in detail the pre-GC B-cell maturation compartment in
blood of CVID patients.
Methods: In this collaborative multicentric study the EuroFlow PID 8-color Pre-GC B-cell
tube, standardized sample preparation procedures (SOPs) and innovative data analysis
tools, were used to characterize the maturation profile of pre-GC B-cells in 100 CVID
patients, vs 62 age-matched healthy donors (HD).
Results: The Pre-GC B-cell tube allowed identification within pre-GC B-cells of three
subsets of maturation associated immature B-cells and three subpopulations of matureorg February 2021 | Volume 11 | Article 6039721
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Frontiers in Immunology | www.frontiersin.naïve B-lymphocytes. CVID patients showed overall reduced median absolute counts (vs
HD) of the two more advanced stages of maturation of both CD5+ CD38+/++ CD21het
CD24++ (2.7 vs 5.6 cells/µl, p=0.0004) and CD5+ CD38het CD21+ CD24+ (6.5 vs 17 cells/
µl, p<0.0001) immature B cells (below normal HD levels in 22% and 37% of CVID
patients). This was associated with an expansion of CD21-CD24- (6.1 vs 0.74 cells/µl,
p<0.0001) and CD21-CD24++ (1.8 vs 0.4 cells/µl, p<0.0001) naïve B-cell counts above
normal values in 73% and 94% cases, respectively. Additionally, reduced IgMD+ (21 vs 32
cells/µl, p=0.03) and IgMD- (4 vs 35 cells/µl, p<0.0001) MBC counts were found to be
below normal values in 25% and 77% of CVID patients, respectively, always together with
severely reduced/undetectable circulating blood pb. Comparison of the maturation
pathway profile of pre-GC B cells in blood of CVID patients vs HD using EuroFlow
software tools showed systematically altered patterns in CVID. These consisted of: i) a
normally-appearing maturation pathway with altered levels of expression of >1 (CD38,
CD5, CD19, CD21, CD24, and/or smIgM) phenotypic marker (57/88 patients; 65%) for a
total of 3 distinct CVID patient profiles (group 1: 42/88 patients, 48%; group 2: 8/88, 9%;
and group 3: 7/88, 8%) and ii) CVID patients with a clearly altered pre-GC B cell maturation
pathway in blood (group 4: 31/88 cases, 35%).
Conclusion: Our results show that maturation of pre-GC B-cells in blood of CVID is
systematically altered with up to four distinctly altered maturation profiles. Further studies,
are necessary to better understand the impact of such alterations on the post-GC defects
and the clinical heterogeneity of CVID.Keywords: CVID, Pre-GC B-cell tube, pre-GC maturation pathway, expression markers, EuroFlow standardizationINTRODUCTION
Common Variable Immunodeficiency (CVID) is the most
prevalent symptomatic primary immunodeficiency (PID). It is
characterized by defective antibody production that leads to
hypogammaglobulinemia (1–3) with an increased susceptibility
to infections, associated in some CVID patients with
enteropathy, autoimmunity, lymphoproliferation, and/or risk
of lymphoid malignancy due to more profound immunological
dysregulation (4, 5). Despite distinct monogenic defects are
present in a minor fraction (<20%) of cases, and other
complex oligo or polygenic genetic predisposition (6), and
epigenetic alterations (e.g., impaired demethylation in genes
relevant for the B cell functions) have been associated with the
development of CVID (7), a well-defined pathogenic mechanism
still remains to be identified in most CVID patients. Thus,
assessment of the distribution of lymphocytes, particularly
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org 2cells in blood of suspicious patients by flow cytometry has
become of great relevance for the diagnosis and classification
of CVID (8, 9).
Impaired post-GC B cell maturation in the periphery (i.e., in
blood and secondary lymphoid tissues) is a hallmark of CVID.
However, CVID is a rather heterogeneous disease from the
clinical, genetic and immunologic point of view. Thus, several
classification algorithms have been proposed for CVID, which
are based on the specific alterations encountered for the major B
cell populations in blood (8), their proliferation history and
somatic hypermutation levels (9), in combination or not with the
clinical manifestations of the disease and/or more sophisticated
computational (i.e., hierarchical clustering) approaches (10).
Overall, impaired differentiation of mature post-GC B-cells,
consisting of severely reduced circulating class-switched
memory B-cells (MBC) and strongly decreased (i.e.,
undetectable) plasmablast/plasma cell production, are the most
consistent defects in CVID. Because of this, demonstration of
reduced class-switched MBC is now used among the diagnostic
criteria proposed by the European Society for Immunodeficiencies
(ESID) for CVID (11). In turn, depending on the specific defects
encountered in the post-GCMBC and Pb compartments in blood,
and the severity of such defects, distinct CVID patient subgroups,
associated with distinct clinical profiles, have also been
identified (12).
Apart from the alterations in post-GC B-cells and
plasmablasts/plasma cells, an increasing number of evidencesFebruary 2021 | Volume 11 | Article 603972
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marrow (BM) is also altered in at least a fraction (e.g., around
one third) of all CVID patients due to either a maturation
blockade (13) and/or an altered bone marrow environment
which is non-permissive for B-cell maturation (14). Thus, a
significant proportion of CVID patients display reduced absolute
B-cell counts in blood (5) and an early B-cell maturation arrest in
BM (15). In addition, expansion of transitional/immature B cells,
and CD21low B-cells has also been reported in a subset of CVID
patients (8, 16). Altogether, these findings further support an
impaired maturation of pre-GC B-cells in CVID.
Herein, we investigated in detail the pre-GC B-cell
maturation compartment in blood of 100 CVID patients,
taking advantage of the novel and standardized flow
cytometric approaches developed by EuroFlow for this purpose
(17–19), e.g., the recently proposed EuroFlow PID 8-color
antibody panels (20) that can be easily implemented in most
diagnostic laboratories worldwide, together with the EuroFlow
standard operating procedures (SOPs) for sample preparation,
data acquisition and analysis, including innovative data analysis
tools recently developed by EuroFlow to assess normal vs altered
pre-GC B-cell maturation profiles in blood (17, 20–23).MATERIAL AND METHODS
Patients, Controls, and Samples
Overall, 100 adult CVID patients -50 men and 50 women;
median age: 41 years (y); range: 16–82y- and 62 healthy
donors (HD) not related to the patients (33 men and 29
women; median age: 34y; range: 19–67y) were studied in
parallel, at eight different EuroFlow-PID centers. CVID was
diagnosed locally at each center, according to the ESID criteria
(3, 24). Relevant clinical data on CVID patients was obtained
from the patients’ health electronic records or from national
patient registries and collected at each of the 8 participating
centers, including data on: patient age, gender, immunoglobulin
(Ig) levels and response to vaccination at diagnosis, together with
data on prior infections and type of infections (e.g., upper and
lower bacterial respiratory infections, viral and fungal
infections), autoimmunity (e.g., cytopenias, organ-based and
systemic auto-immunity), lymphoproliferation, lymphoid
interstitial pneumonitis (LIP), granulomas, splenomegaly,
hepatomegaly, bronchiectasias, enteropathy, and malignancy,
as well as prior therapy, including Ig replacement therapy.
Blood samples were obtained, processed and measured by
flow cytometry at each of the 8 participating centers after
informed consent had been given by each individual
participant, according to the principles of the Declaration of
Helsinki. The study was approved by the local Ethics Committees
of the participating centers: Hospital Universitario La Paz,
Madrid, Spain (PI-2833 and 2009/3348/I); Charles University,
Prague, Czech Republic (15-28541A); Erasmus MC, Rotterdam,
The Netherlands (MEC-2013-026); St Anne´s University, Brno,
Czech Republic (METC 1G2015); BRC-Translational
Immunology Lab, University of Oxford, Oxford, UnitedFrontiers in Immunology | www.frontiersin.org 3Kingdom; University of Salamanca, Salamanca, Spain (USAL/
CSIC 20-02-2013); University Hospital of Ghent, Belgium
(B670201523515); and Faculdade de Medicina da Universidade
de Lisboa and Centro Hospitalar Universitário Lisboa Norte,
Lisbon, Portugal (937/13).
Flow Cytometric Identification of B-Cells,
Plasmablasts/Plasma Cells and Their
Subsets in Blood
Blood samples from both CVID patients and HD were processed
and stained at each center with the EuroFlow 8-color PIDOT and
Pre-GC B-cell tubes, following the EuroFlow SOPs for staining of
cell surface membrane (sm) markers only, as previously
described (20–22). Details about the specific antibody clones
and fluorochrome-conjugated reagents used are provided in
Supplementary Table 1. Instrument set-up and calibration
were performed prior to data acquisition on ≥1 x 106 cells
(range: 1 x 106-5 x 106 cells) in FACSCanto II flow cytometers
−Becton/Dickinson Biosciences (BD), San José, CA-, following
the EuroFlow SOPs available at www.EuroFlow.org (21). Data
analysis was performed centrally on pseudoanonymazed flow
cytometry standard (FCS) data files deposited in the EuroFlow
data repository, using the Infinicyt software (Cytognos SL,
Salamanca, Spain).
For data analysis, a standardized gating strategy was used for
identification of all pre-GC (defined as CD19+ CD27- sIgM+ B-
lymphocytes) and post-GC B-cell subsets (defined as CD19+
CD27+ or CD19+ CD27- smIgM- B-cells) present in blood, based
on the EuroFlow-PID Pre-GC B cell tube as illustrated in
Supplementary Figure 1. Briefly, CD19+ B-cells and
plasmablasts/plasma cells were both identified by their low-to-
intermediate forward (FSC) and sideward (SSC) light scatter
properties after excluding debris and cell doublets. Subsequently,
both cell subsets were sub-classified into 11 different subsets
based on their staining profile for CD19, CD38, CD24, CD21,
CD27, CD5, smIgM, and smIgD: a) CD27- CD38hi CD24hi CD5+
smIgM++D+ immature/transitional B cells; b) CD27- CD38-
CD24het CD5het smIgM+IgD++ mature naive B lymphocytes; c)
CD27+ CD38lo CD5- CD24het smIgM++D+ (MD+) unswitched
MBCs; d) CD27+/- CD38lo CD5- CD24het smIgM-D- (MD-)
switched MBCs; and, e) CD27++ CD38hi CD5- CD21- CD24-
plasmablasts/PCs. Immature/transitional B cells were further
sub-classified according to the pattern of expression of CD38,
CD5, CD21, and CD24 into three subsets of increasingly more
mature B-lymphocytes: a1) CD5- CD38++ CD21het CD24++; a2)
CD5+ CD38+/++ CD21het CD24++, and a3) CD5+ CD38het CD21+
CD24+ immature/transitional B lymphocytes. In turn, mature
naive B-lymphocytes and unswitched MBCs were also further
sub-classified into three subsets each, based on the expression
profile for CD21 and CD24, into CD21+ CD24+, CD21- CD24++,
and CD21- CD24- mature naïve B cells and unswitched
MBC, respectively.
For each B cell population, absolute counts were calculated
using a dual platform assay based on the white blood cell (WBC)
count, as assessed in a conventional hematological cell counter,
and the percentage of total B cells obtained with the PIDOT tubeFebruary 2021 | Volume 11 | Article 603972
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reference ranges were defined by the 5th and 95th percentile
values observed in blood of 62 (age- and sex-matched) HD
analyzed in parallel to the CVID patients (Supplementary
Table 2).
Pre-GC B-Cell Maturation Pathway
in Blood
A database reflecting the normal B-cell maturation pathway of
pre-GC B-lymphocytes in blood was built by merging data files
from 18 representative HD, using the Infinicyt software
(Cytognos SL) and previously described procedures (25). For
this purpose, pre-gated data files which specifically contained
gated data exclusively on the three different subsets of immature
blood B cells (CD5- CD38++ CD21het CD24 ++, CD5+ CD38+/++
CD21het CD24++ and CD5+ CD38het CD21+ CD24+ immature B
cells), together with both the CD21+ CD24+ and CD21- CD24-
mature naive B cell subsets, from blood of 18 HD stained with
the Pre-GC B-cell tube were merged into a single data file. MatureFrontiers in Immunology | www.frontiersin.org 4naive CD21- CD24++ B cells were not included in the pre-GC B-
cell database since this subset is barely detectable in normal
blood from HD (26). Then, the merged data file was used to
define the maturation pathway of pre-GC B-cells using the
maturation tool developed by EuroFlow and implemented in
Infinicyt (v2.0-4b for EuroFlow members only). This tool allows
for automatic i) definition of vectors that reflect maturation
pathways based on curve analysis algorithms, ii) classification of
events into different maturation stages arbitrarily set at equal
distances, iii) calculation of descriptive statistics for all events
classified within each maturation stage, followed by direct
visualization in a (balanced) 3-dimension (3D) APS
(automated population separator) diagram, constructed using
the first three principal components (PC1 to PC3) derived from
PC analysis (PCA) performed with the Infinicyt software (Figure
1A). Thus, based on the maturation tool of the Infinicyt software,
10 distinct pre-GC B-cell maturation stages were (arbitrarily)
defined and the normal mean fluorescence intensity (MFI) range
(2SD) per maturation stage was calculated for each individualA
B
FIGURE 1 | Illustrating example of the normal (reference) pre-germinal-center (GC) maturation pathway. Overall phenotypes (A) and expression levels for individual
markers per stage of maturation (B) are shown for each individual donor (n=18) included in the normal reference pre-GC B-cell maturation pathway used to define
reference normal values, depicted as color-coded lines per marker/parameter.February 2021 | Volume 11 | Article 603972
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vector defined by the median MFI values per maturation stage
(n=10) data was plotted for the whole set of phenotypic markers
included in the EuroFlow Pre-GC B-cell tube (Figure 1A).
Subsequently, median (range) and mean (+2 SD) fluorescence
intensity (MFI) values per marker in HD blood pre-GC B-cells
together with the corresponding B cell percentage, were plotted
along the different maturation stages and used as normal
reference range (Figure 1B). Subsequently, gated pre-GC B-
cells from every individual CVID case were plotted against the
normal reference maturation database and differences in MFI
values vs. the normal blood range were recorded per marker for
each of the 10 pre-established pre-GC B-cell maturation stages.
MFI values below 2SD or above 2SD of the normal reference
range (per maturation stage) for at least two consecutive stages of
maturation of pre-GC B-cells, were considered to be altered. In
parallel, a graphical display of the values per marker along the
pre-GC B-cell maturation pathway, in which each patient is
represented against the database, was obtained.Statistical Analyses
Statistical analyses were performed with GraphPad Prism
Software version 6.0 (Graph- Pad software, San Diego, CA). To
define normal ranges for each B cell subset identified in blood, 5th
and 95th percentile values from the 62 adult HD were used.
Group comparisons were performed using the Mann-Whitney U
and Kruskal-Wallis tests (for continuous variables) or the Fisher
exact and X2 tests (for categorical variables). Clustering analysis
based on K-means was performed using the JMP software (free
trial version 14; SAS Institute Inc., Cary, NC) based on the
immunophenotypic profiles and relative distributions of pre-GC
B-cells along the pre-GC maturation pathway, per maturation
stage. Cluster analysis was performed by simultaneously
comparing the MFI values for each surface marker and the
percentage of events per stage of maturation per CVID patient
against the maturation reference database. P-values<0.05 were
considered to be associated with statistical significance and coded
hereafter as follows: *p-value<0.05; ** p-value<0.01; *** p-
value<0.001; and, **** p-value<0.0001.RESULTS
Distribution of Pre-GC B-Cell Subsets
in Blood of CVID Patients
Based on the data provided by the PID-orientation tube (PIDOT)
(22), and the Pre-GC B-cell tube, detailed characterization of B
cells in peripheral blood was achieved for a total of 11 distinct B
cell subsets: i) immature/transitional B-cells (including three
maturation-associated populations of CD5- CD38++ CD21het
CD24 ++, CD5+ CD38+/++ CD21het CD24++, and CD5+
CD38het CD21+ CD24+ immature B-cells); ii) mature naïve B-
cells (and their three CD21+ CD24+, CD21- CD24++, and CD21-
CD24- subsets); iii) unswitched IgMD+, IgM+-only, and IgD+
-only MBC (and their CD21+ CD24+, CD21- CD24-, and CD21-Frontiers in Immunology | www.frontiersin.org 5CD24++ subsets); iv) switched IgMD- MBC; and v) plasmablasts/
plasma cells (Figures 2A–C).
Overall, the total B-cell count in blood ofCVIDwas significantly
reduced vs. age-matchedHD (median: 149 vs 206 cells/µl; p=0.04).
Suchdecreasewasmostlydue toa significant reductionof immature
B-cells (11 vs 27 cells/µl, p<0.0001), IgMD+MBC (21 vs 32 cells/µl,
p=0.03) and particularly, IgMD- MBC counts (4 vs 35 cells/µl,
p<0.0001), in the absence of virtually no plasmablasts/plasma cells
(Figure 3A). Despite the overall reduced median B-cell counts
observed in CVID, a significant overlap with HDwas still observed
with variable frequencies and patterns of alteration among CVID
patients. Thus, decreased counts below normal values (<5th
percentile of age-matched HD) of IgMD- MBC were detected in
77% of the CVID patients investigated, together with undetectable
plasmablasts/plasma cells in 100% of cases. In contrast, reduced
immature/transitional B cells and IgMD+ MBC counts were only
found in 29% and 25% of cases, respectively (Figure 3A). In turn,
only a small percentage of all CVID patients showed reduced
mature naïve B-cell counts (11%). Altogether, the decreased
numbers of the distinct B-cell subsets led to overall low total B-
cell counts in blood of 21% of all CVID patients (Figure 3A).
More detailed analysis of the pre-GC B-cell compartment also
showed distinct patterns of alteration for different subsets of
immature B-cells and mature naive B-cells. Thus, reduced counts
(vs age-matched HD) of the more advanced stages of maturation
of CD5+ CD38+/++ CD21het CD24++ (2.7 vs 5.6 cells/µl,
p=0.0004) and CD5+ CD38het CD21+ CD24+ (6.5 vs 17 cells/
µl, p<0.0001) immature/transitional B cells was detected in 22%
and 37% of CVID patients. In contrast, the less differentiated
CD5- CD38++ CD21het CD24 ++ immature/transitional B
lymphocytes (0.79 vs 0.89, p>0.05) were decreased in blood in
only 7% of CVID patients (Figure 3B). Regarding mature naive
B-cells, an increase in CD21-CD24- (6.1 vs 0.74 cells/µl,
p<0.0001) and CD21- CD24++ (1.8 vs 0.4 cells/µl, p<0.0001)
naive B cell counts was observed in CVID vs. HD, with a clear
bimodal distribution (Figure 3B) due to the presence of a major
subgroup of patients (73% and 94%, respectively) presenting a
significant expansion of these two naive B-cell subsets, in
association or not with low CD21+ CD24+ naïve B-cell counts,
which were found to be reduced in only 21% of CVID patients
(Figure 3B).
Regarding post-GC MBC, CVID patients displayed a
significant reduction (vs. HD) of CD21+ CD24+ IgMD+ MBC
(16 vs 31 cells/µl, p=0.0006), associated with normal or slightly
increased (p>0.05) CD21-CD24- and CD21- CD24++ IgMD+
MBC numbers (Supplementary Figure 2). Plasmablasts/
plasma cells, were either not detected or severely reduced in
100% of CVID patients. Altogether, these results suggest the
existence of different maturation blockades and profiles in CVID,
which frequently also involve pre-GC B-cells, in addition to post-
GC MBC and plasmablasts/plasma cells.
Pre-GC B-Cell Maturation Profile in
Normal Blood
Based on the innovative maturation tools developed by
EuroFlow (18, 25), a normal pre-GC B-cell referenceFebruary 2021 | Volume 11 | Article 603972
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an methods section and illustrated in Figure 1A.
Detailed analysis of the normal pre-GC B-cell maturation
profile showed downregulation of CD38 from stage 3 on,
associated with strong CD5 and CD24 expression at early
stages (stages 2–4 and stages 1–3, respectively), CD5 becoming
negative from stage 7 onwards while CD24 progressively
decreased from stage 4 onward; in turn, CD21 was strongly
expressed from stage 1 until the last stages of maturation (stages
9 and 10), when it was downregulated. Among the other markers
investigated, smIgM showed slightly higher expression levels at
early (stages 1–3) vs later stages with stable levels from stage 4 to
10, while IgD and CD19 showed similarly stable expression levels
along all stages of maturation of pre-GC B-cells. By definition
CD27 was not expressed in pre-GC B-cells (Figure 1B).Frontiers in Immunology | www.frontiersin.org 6Altered Maturation Profiles of Blood
Pre-GC B-Cells in CVID
Direct comparison of the phenotype of maturation-associated
blood pre-GC B-cell subsets from CVID patients vs. the normal
maturation was performed in 88 patients by plotting phenotypic
data from each CVID against the normal reference maturation
database (Figures 4 and 5). For better visualization of the
phenotypic deviations from normal, a normalized scale
(Supplementary Figure 3) was used. Overall, distinct patterns
of alteration (cell counts and/or MFI values per marker in ≥2/10
consecutive stages of maturation of pre-GC B-cells falling ≥2 SD
apart from the normal distribution) of the pre-GC B-cell
maturation were detected in every case (88/88; 100%). Thus,
four distinct patterns of alterations were identified: a) CVID with
normally-appearing maturation pathways (groups 1 to 3) butA B
C
FIGURE 2 | Distribution of the major subsets of immature, naive and memory B cells (MBC) and plasmablasts/plasma cells (A), including the different subsets of
pre-germinal-center (GC) B-cells (B), in blood of a representative adult healthy donor (HD) and their maturation-associated relationship (C). Three-dimensional
principal component (PC) analysis (PCA) plots in (A, B) were built based on PC1 (A: mean fluorescence intensity of CD27, 29.25%; IgD, 22.56%; IgM, 20.45%;
CD21, 11.16%; CD38, 9.63% and CD5, 6.95%; B: mean fluorescence intensity of CD21, 30.15%; CD24, 27.64%; CD38, 23.07% and CD5, 19.14%), PC2 (A:
mean fluorescence intensity of IgM, 43.89%, CD27, 34.62%, CD38, 10.18%, IgD, 9.96%; CD21, 1.16% and CD5, 0.18%; B: mean fluorescence intensity of CD21,
43.66%, CD38, 23.62%, CD24, 17.09% and CD5, 15.63%) and PC3 (A: mean fluorescence intensity of CD38, 42.02%, CD21, 19.56% CD27, 12.19%, CD5,
12.03%, IgD, 11% and IgM, 3.20%; B: mean fluorescence intensity of CD5, 56.16%, CD24, 27.80%, CD38, 14.85% and CD21, 1.19%) vectors using the
(balanced) automated population separator (APS1-2) 3-D view of Infinicyt. In both (A, B), the distinct color-coded cell populations displayed were gated as described
in Supplementary Figure 1.February 2021 | Volume 11 | Article 603972
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individual phenotypic markers (57/88, 65%) and b) CVID
patients with a clearly altered pre-GC B-cell maturation
pathway (31/88 cases, 35%; CVID group 4) (Figures 4A and
B). In turn, unsupervised clustering analysis further revealed the
presence of three different profiles among the former CVID
patient groups 1 to 3, depending on the pattern of deviation in
the number of cells per maturation stage and the levels of
expression of individual markers, from the normal reference
maturation pathway (Figure 5 and Supplementary Figure 3).
In group 1 a large fraction of CVID patients (42/88, 48%) was
included, who showed significantly reduced total B-cell (128 vs
206 cells/µl, p=0.008) and both CD5+ CD38+/++ CD21het CD24++
(2.6 vs 5.6 cells/µl, p=0.0013) and CD5+ CD38het CD21+ CD24+
(7.3 vs 17 cells/µl, p<0.0001) immature/transitional B-cellFrontiers in Immunology | www.frontiersin.org 7numbers, in the absence of overall relevant phenotypic
deviations from the normal maturation profile of blood pre-
GC B-cells (Supplementary Figure 3). Group 2 consisted of 8/88
(9%) CVID patients that showed overexpression of smIgM at
intermediate stages of maturation of pre-GC B-cells and of CD38
at early and late stages of maturation of pre-GC B-cells;
compared to HD, CVID cases classified in group 2 also
showed significantly higher counts of the most immature CD5-
CD38++ CD21het CD24 ++ (7.6 vs 0.89 cells/µl, p=0.0009) pre-GC
B-cell subset, associated with reduced numbers of more
differentiated CD5+ CD38het CD21+ CD24+ immature B
lymphocytes (5.1 vs 17 cells/µl, p=0.0183) and IgMD+
(particularly CD21+ CD24+) MBC (4 vs 31 cells/µl, p<0.0001);
in addition, group 2 patients also showed decreased levels of
CD21 at stages 7–8, reflecting the parallel increase in CD21-A
B
FIGURE 3 | Distribution of distinct subsets of pre-germinal-center (GC) and post-GC B-cells in blood of Common Variable Immunodeficiency (CVID) patients (n=100)
vs age-matched HD (n=62). (A) absolute counts of major pre-GC and post-GC B-cell subsets are shown using box and whiskers plots separately for healthy donor
(HD) (n=62) and CVID patients (n=100) where horizontal lines and vertical lines represent the median and both 5th and 95th percentile values, respectively.
Percentage of CVID patients with decreased or increased counts below or above normal values (<5th and >95th percentile) detected in age-matched HD are shown
as percent values. (B) absolute pre-GC CD5- CD38++ CD21het CD24+++, CD5+ CD38+/++ CD21het CD24++, and CD5+ CD38het CD21+ CD24+ immature B-cell and
CD21+CD24+, CD21-CD24-, and CD21- CD24++ naïve B-cell subset counts in CVID vs HD. N.S. not statistically significant differences detected, *p-value<0.05;
***p-value<0.001; ****p-value<0.0001 (Mann Whitney U test).February 2021 | Volume 11 | Article 603972
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Finally, group 3 included 7/88 (8%) CVID patients characterized
by showing under-expression of CD38 together with higher
levels of CD24 at the last stages of maturation of pre-GC B-
cells, in line with the underlying increased counts of
CD21+CD24+ mature naïve B cells observed among these cases
vs. the other CVID patient groups 1 to 3: 137 vs 76, 42, and 59
cells/µl in CVID groups 1, group 2, and group 4, respectively
(Table 1).
As referred above, group 4 CVID patients presented clearly
altered pre-GC B-cell maturation profiles, the most commonFrontiers in Immunology | www.frontiersin.org 8alteration (31/31 cases) in their blood pre-GC B-cells consisting
of absence/decreased number of cells at the earliest stages of
maturation (stages 1-3). In addition, group 4 CVID patients
showed abnormally lower counts in blood of CD5- CD38++
CD21het CD24++ -0.36 vs 0.98, 7.6, 1.6, and 0.89 cells/µl in
group 1 (p=0.015), group 2 (p<0.0001) group 3 (p=0.003)
patients and HD (p=0.004), respectively- and CD5+ CD38+/++
CD21het CD24++ -1.4 vs 2.6, 12 and 5.6 cells/µl, group 1 (p=0.03),
group 2, (p=0.0117) CVID patients and HD (p<0.0001)-,
immature/transitional B cells, together with significantly higher
counts of CD21- CD24- -9.9 vs 4, 0.74 cells/µl in CVID group 1A
B
FIGURE 4 | Illustrating 2-dimensional and 3-dimensional dot plot graphical examples of the maturation pathway of pre-GC B-cells in representative Common
Variable Immunodeficiency (CVID) patients showing normal-appearing (A; CVID groups 1–3) vs severely disturbed maturation pathways (B; CVID group 4). In all
plots, the reference pre-germinal-center (GC) B-cell maturation pathway defined for 18 (individual) HD green lines is shown together with a gray/black line
corresponding to the maturation pathway of the two individual CVID patients shown in (A, B), respectively. Colored dots correspond to the median values obtained
for the 10 different maturation stages (color code defined in the right) where stage 1 is colored as blue and stage 10 is depicted in red.February 2021 | Volume 11 | Article 603972
del Pino-Molina et al. Dissection of the Pre-GC B-Cell Maturation Pathway in CVIDFIGURE 5 | Maturation diagrams per marker of all Common Variable Immunodeficiency (CVID) patients included in each of the three CVID groups of patients
displaying a normal-appearing pre-GC maturation profile in blood (groups 1–3). In each diagram the (normalized) reference maturation pathway is shown as a grey
area for the ±2 SD of normal MFI values per marker. The pre-GC B-cell maturation profile found in CVID patients from each group is displayed as ±2 SD bars color-
coded by CVID patient group (CVID group 1 is shown in blue, group 2 in green and group 3 in pink). Values below or above the normal 2SD limit for ≥ 2 consecutive
maturation stages were considered to reflect an altered marker expression profile.Frontiers in Immunology | www.frontiersin.org February 2021 | Volume 11 | Article 6039729
del Pino-Molina et al. Dissection of the Pre-GC B-Cell Maturation Pathway in CVIDcases (p=0.0018) and HD, (p<0.0001) respectively- and CD21-
CD24++ mature naïve B-cells -3.5 vs 1.5 and 0.4 cells/µl, in group
1 patients (p=0.02) and HD, (p<0.0001) respectively-(Table 1).
In addition, group 4 CVID patients also showed significantly
increased blood counts vs HD of CD21- CD24- (1.15 vs 0.66
cells/µl, p=0.016) and CD21- CD24++ (4.1 vs 1.18 cells/µl,
p=0.003) MBC cells, compared to with the other CVID
(groups 1–3) cases (Table 1).
From the clinical point of view, no major differences were
observed among the patients included in the distinct CVID
groups 1 to 4, except for a higher frequency of autoimmune
cytopenias in group 4 patients vs. groups 1–3 cases (23% vs 6%,Frontiers in Immunology | www.frontiersin.org 10p=0.032), and a greater prevalence in group 2 patients of
lymphadenopathy (63% vs. 15%, 33%, 23% in group 1, 3, and
4 cases, respectively; p=0.03) and systemic autoimmunity (25%
vs. 0%, 16% and 3% in groups 1, 3, and 4, respectively; p=0.009)
(Supplementary Table 3).DISCUSSION
CVID is yet a poorly understood, clinically and prognostically
heterogeneous disease, whose clinical management remains a
challenge. Due to the lack of diagnostic genetic/molecularTABLE 1 | Distribution of different subsets of blood B-cells in HD and CVID patients classified according to the presence of a normal-appearing (CVID groups 1-3) vs
severely disturbed maturation pathway (CVID group 4).
B-cell subset CVID patients group p-value (vs HD) p-value
(among CVID groups)
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lymphocyte populations in blood, in combination with other
laboratory data, has become critical for diagnosis and monitoring
of CVID. Thus, at present it is well-established that
simultaneously decreased plasmablast/plasma cell and/or
switched-MBC counts in blood is a hallmark of CVID (8, 9,
12). Despite pre-GC B-cells appear to be preserved in a
substantial proportion of CVID patients, an altered B-cell
maturation in bone marrow together with reduced total B-
cells, and an expansion of both immature B lymphocytes and
CD21low B cells in blood, have been recurrently reported in a
subset of CVID patients (8, 13–16, 27, 28). Here, we investigated
in detail the presence and frequency of alterations in both the
numerical distribution and the immunophenotypic (maturation)
profile of pre-GC B-lymphocytes based on a large cohort of 100
CVID patients from 8 different European centres in comparison
to age-matched HD. For this purpose we used the standardized
EuroFlow pre-GC B-cell tube and SOP (19–21) together with
novel B-cell maturation software tools. Overall our results
confirmed the presence of significantly reduced plasmablast/
plasma cell counts in every CVID patient, most frequently
associated with decreased switched-MBC. Despite total B-cell
counts were significantly reduced in CVID vs age-matched HD,
less than a third of all CVID patients investigated here showed
abnormally decreased pre-GC B-cell counts in blood, in line with
(extensive) previous observations by our and other groups (8, 9).
In order to gain further insight into the (potentially) altered
pre-GC B-cell profiles in CVID, we dissected the pre-GC
compartment into five distinct maturation-associated subsets
of pre-GC immature and naïve B-cells. Overall, immature B
cells were decreased in almost one third of the patients, while
more mature naive B-lymphocytes were found to be below
normal levels in only 11% of cases. Altogether these findings
point out a defective B cell production and/or shortened survival
of immature B cells (9) in a significant proportion of CVID cases.
In line with this hypothesis, more in depth analysis of the
immature and naive compartments of pre-GC B-cells showed
that while <10% of CVID patients had lower counts in blood of
the less differentiated CD5- CD38++ CD21het CD24 ++ immature
B-lymphocytes, more than a third of the cases showed reduced
counts of the more differentiated CD5+ CD38het CD21+ CD24+
immature B-cells. In addition, this maturation blockade at the
earliest stages of peripheral immature B-lymphocytes was
associated with increased counts of the minor subsets of the
more mature CD21- (CD24- and CD24-++) naive B-cells in
virtually every CVID patient, as also extensively described
previously by others in the literature (29–32). Thus, Vlková
et al. (33) first reported that CD21- B-lymphocytes expanded
in CVID mostly comprise the CD21- CD24- and CD21- CD24++
subsets. Despite the precise functional and clinical significance of
both subsets still remains unclear, it has been previously shown
that homeostatic stimulation of CD21- B-cells induces
proliferation of naive B-cells with loss of CD21 expression and
differentiation toward CD21-CD24- and CD21-CD24++ B-cells,
in the absence of the classic GC reaction (33). However, in
contrast to healthy individuals in whom the majority of CD21lowFrontiers in Immunology | www.frontiersin.org 11B-cells belong to the MBC compartment (29, 34), in CVID
patients these cells have not undergone somatic hypermutation
and show naïve B-cell features (35, 36) in line with our findings.
Of note, expanded CD21- B-cells have also been associated with
T-bet+ B-cells in humans (37) and with interferon-gamma
mediated dysregulation of B cell maturation induced by
follicular helper T cells in CVID (38).
Normal differentiation and survival of immature/transitional
and mature naive B-cells requires integration of distinct
molecular signals after B-cells are released from the BM to the
periphery (39). Thus, almost 40% immature peripheral blood B-
cells produced in human bone marrow may be autorreactive (39,
40); at this stage, peripheral tolerance is checked and only a small
percentage of all circulating immature B-lymphocytes will
survive the negative selection and become mature naive B-cells
(40). Immature B-cells retain low expression levels of BM-
associated markers such as CD10, CD38, CD24 (41), and
except for the less differentiated immature B-cells that are CD5
negative, they are also CD5+. In turn, recent BM emigrant
immature B-cells express high levels of smIgM which
contribute to the negative selection based on the B cell
receptor (BCR) affinity for self-antigens (42). Further
maturation of immature B-cells and mature naive B-cells is
associated with loss of expression of CD38 and CD5, and
down-regulation of CD24 levels (41, 43–45). CD38 has
enzymatic activity and modulates peptide concentrations
during B-cell signalling, and it is strongly expressed in the GC
reaction where it prevents apoptosis of GC B-cells (43, 46). CD24
is also highly expressed on immature B-cells and it is associated
with Siglec-10 that interacts with SHP-1 phosphatases, a
complex implicated in NFkB activation and the prevention of
signaling from non-specific antigen receptors (47). In turn, the
CD21 complement receptor is part of the BCR co-receptor
complex (CD19, CD21, CD81, and CD225) (48), that acts as
positive regulator of antigen-mediated BCR signaling, a critical
event for normal maturation of transitional B-cells (39) into
naïve B-lymphocytes, and the differentiation of the later cells to
MBC and plasma cells. Thus, CD21 reduces the B-cell activation
threshold and contributes to amplification of BCR signaling (30).
In contrast, CD5 is a negative regulator of BCR signaling that
limits B-cell activation to avoid autorreactivity during the early
steps of B-cell maturation in blood, while contributing to
upregulate the BCR/TCR activation threshold after antigen
recognition (44, 49, 50). Consequently, high levels of CD5
expression together with low CD21 expression on immature B-
cells, avoid autorreactivity (43). Altogether, these findings
support the notion that transitional/immature B-cells are
particularly sensitive to subtle variations in stimuli and signals
that determine cell death vs survival, on a delicate equilibrium
that avoids excessive auto-reactivity while ensuring production
of a sufficiently wide BCR repertoire, via further differentiation to
mature naive B-lymphocytes. In addition, our findings about an
altered numerical distribution of distinct maturation-associated
subsets of immature B-cells and mature naive B-lymphocytes in
CVID, suggest potential (co)existence of maturation blockades at
the earliest stages of maturation of peripheral immature B-February 2021 | Volume 11 | Article 603972
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toward less reactive CD21- naive B-cells, that might finally lead
to decreased plasma cell and switched memory B-cell counts in
these patients. If this hypothesis holds true, an altered
maturation of pre-GC B-cells would also be a hallmark of
CVID, even among patients that show normal pre-GC B-
cell counts.
In order to investigate in more depth the potential existence of
an altered maturation of pre-GC B-cells in CVID toward CD21-
naïve B-lymphocytes, we built a normal (reference) database to
trace the maturation of pre-GC B-lymphocytes from the less
differentiated transitional/immature to the more mature naive B-
cells. As expected, the normal (HD) database, showed that CD38,
CD5, CD24, and smIgM are downregulated in the transition
between immature/transitional B-cells and mature naive B-
lymphocytes, in line with previous observations (42, 43). In
contrast, comparison of individual CVID patients against the
normal reference pre-GC B-cell maturation pathway, revealed
altered marker expression profiles in every CVID patient
analyzed, including four clearly different patterns of alteration.
Thus, in around one third of the cases (CVID group 4) reduced
numbers of immature/transitional B-cell subsets associated with
increased counts of CD21- naïve and unswitchedMBCwere found
to be the consequence of a completely deregulated pre-GC B-cell
maturation associated also with immunophenotypes for one or
more markers that deviated significantly from those of normal
pre-GC B-cells. Of note, among CVID group 4 patients, the altered
immunophenotypic pre-GC B-cell maturation profiles and pre-
GC B-cell counts were associated with a significantly higher
frequency of systemic autoimmunity, as also reported by others
(51), suggesting a potential failure of the negative selection of
immature B-cells in BM, and a parallel attempt to keep B-cell
production (and mature B-cell numbers) within the normal range.
In contrast, pre-GC B-cell counts were less severely reduced in the
other three CVID patient groups here identified, in line with the
observation in these groups of patients of more conserved,
normally-appearing, pre-GC B-cell maturation profiles. Despite
this, multiple alterations on the expression levels of specific cell
surface molecules along the pre-GC B-cell maturation pathway
were observed in these patients, particularly in the CVID group 2
and group 3 here identified.
Similarly to CVID group 4 cases, group 1, and particularly
group 2 CVID patients displayed overexpression of smIgM at
intermediate stages of maturation of blood pre-GC B-cells, in
association with significantly reduced switched MBC. In
contrast, CVID group 3 cases showed both normal smIgM
expression levels and closer to normal IgMD- MBC counts.
Downregulation of smIgM expression levels in B-cells at the
latest stage of pre-GC B-cell maturation is required for further
negative selection of autorreactive B-lymphocytes and adequate
B-cell maturation. Thus, the overexpression of SIgM here
observed might contribute to explain the higher frequency of
autoimmune diseases in CVID group 2 patients, in line with
previous findings by Warnatz et al. (27) in a subset (type Ia) of
CVID patients, and also findings of other groups that showed
high expression levels of smIgM and autoimmunity in PID otherFrontiers in Immunology | www.frontiersin.org 12than CVID, reflecting B-cell activation (52) in these patients.
This, together with the presence of higher levels of CD38 at
intermediate stages of maturation of pre-GC B-cells, (which was
also more pronounced in CVID group 2 patients), may reflect
delayed maturation of immature B-cells to mature naive B-
lymphocytes among this subgroup of CVID patients. This may
contribute to explain why compared to the other CVID groups,
CVID group 2 cases were also those who presented the highest
counts of the more immature (CD5- CD38++ CD21het CD24 ++)
blood B-cells. In parallel, lower levels of CD5 (found in common
in the three CVID groups 1 to 3) together with a marked
reduction of the amount of CD19 expressed/B-cell, particularly
in CVID group 2 cases, may further affect the activation
threshold (53) required for BCR-mediated B-cell activation and
subsequent maturation of immature and naive B-lymphocytes to
MBC and plasma cells in this group of CVID patients. In fact,
reduced CD5 expression during pre-GC maturation might lower
the BCR activation threshold responsible for the activation of
autorreactive B-cells. This together with the increased numbers
of CD21- naïve B-cells would contribute to a lower B-cell
(activation) response (36), leading to a more pronounced
anergic state, as previously associated with CD21-/low B cells in
CVID (29, 30) and CD19-CD81 complex immunodeficiency
(48), together with downregulation of B-cell activation
receptors in parallel to upregulation of genes involved in the
inhibition of B-cell proliferation (35). Interestingly, CVID group
2 cases showed partially overlapping clinical and immunological
features to CVID Ia patients who are defined by coexistence of
strongly decreased MBC and expanded CD21low B-lymphocytes,
and show a unique clinical behaviour with greater frequency (vs
CVID Ib and II cases) of autoimmunity and organomegalies (8,
27). Despite these similarities, in our patients expanded CD21-
pre-GC B-cells were not exclusively detected among CVID group
2 patients, but they were also found in other patient groups,
particularly in CVID group 4 cases. Further studies are required
to better understand the relationship that might exist between
both CVID patient groups.
In summary, detailed analysis of the maturation profile of
pre-GC B-cells in CVID compared to normal blood B-cells,
based on the Euroflow Pre-GC B-cell tube and maturation
software tools, revealed systematically altered marker
expression immunophenotypic profiles in CVID, in association
with decreased pre-GC B-cell counts, with up to four distinctly
altered profiles. Further studies in larger cohorts of CVID
patients with longer follow-up are needed to confirm our
results, and to correlate the distinct immune profiles here
described with the underlying CVID-associated monogenic
mutations and polygenic variant profiles, intravenous Ig
therapy and patient outcome.DATA AVAILABILITY STATEMENT
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25. Flores-montero J, Grigore G, Fluxá R, Hernández J, Fernandez P, Almeida J,
et al. EuroFlow Lymphoid Screening Tube (LST ) data base for automated
identification of blood lymphocyte subsets. J Immunol Methods (2019)
475:112662. doi: 10.1016/j.jim.2019.112662
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